



Ascendis Pharma Endocrinology Division A/S

c/o Ascendis Pharma A/S, Tuborg Boulevard 12

DK- 2900 Hellerup

Central Business Registration No. 32 32 35 37

Annual Report 2025

(January 1 - December 31)

Adopted at the Annual General Meeting of the Company on March 23, 2026.

Michael Wolff Jensen
Chairman of the General Meeting

Contents

Company Information	1
Management Statement.....	2
Independent Auditor's Report.....	3
Management Commentary	5
Income Statement 1 January - 31 December.....	8
Balance Sheet 31 December	9
Statement of Changes in Equity	10
Notes to the Financial Statements.....	11

Company Information

Ascendis Pharma Endocrinology Division A/S
c/o Ascendis Pharma A/S
Tuborg Boulevard 12
DK-2900 Hellerup
Central Business Registration No. 32 32 35 37
Registered in: Gentofte
Phone: +45 70 22 22 44
Internet: www.ascendispharma.com
E-mail: info@ascendispharma.com

Board of Directors

Michael Wolff Jensen, Chairman
Jan Møller Mikkelsen
Anni Lotte Kirstine Pedersen

Executive Board

Jan Møller Mikkelsen, Chief Executive Officer

External Auditors

Deloitte Statsautoriseret Revisionspartnerselskab
Weidekampsgade 6
DK-2300 Copenhagen S

Management Statement

The Executive Board and Board of Directors have today considered and adopted the Annual Report of Ascendis Pharma Endocrinology Division A/S for the financial year 1 January - 31 December 2025.

The Annual Report is prepared in accordance with the Danish Financial Statements Act.

In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2025 of the Company and of the results of the Company operations for 2025.

We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Hellerup, March 23, 2026

Executive Board

Jan Møller Mikkelsen
Chief Executive Officer

Board of Directors

Michael Wolff Jensen
Chairman

Jan Møller Mikkelsen

Anni Lotte Kirstine Pedersen

Independent Auditor's Report

To the Shareholder of Ascendis Pharma Endocrinology Division A/S

Opinion

We have audited the financial statements of Ascendis Pharma Endocrinology Division A/S for the financial year 01.01.2025 - 31.12.2025, which comprise income statement, balance sheet, statement of change in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2025 and of the results of its operations for the financial year 01.01.2025 - 31.12.2025 in accordance with the Danish Financial Statements Act.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements and the parent financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required by relevant law and regulations.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of the management commentary.

Copenhagen, March 23, 2026

Deloitte

Statsautoriseret Revisionspartnerselskab

CVR No 33 96 35 56

Niels Skannerup Vendelbo
State Authorised Public Accountant
Identification No (MNE) 34532

Rie Merete Kjær Larsen
State Authorised Public Accountant
Identification No (MNE) 43596

Management Commentary

Unless the context otherwise requires, references to the “Company,” “we,” “us” and “our” refer to Ascendis Pharma Endocrinology Division A/S.

Key Figures

*Key ratios are calculated as follows:

	<u>2025</u>	<u>2024</u>	<u>2023</u>	<u>2022</u>	<u>2021</u>
(EUR'000)					
Revenue	140,817	122,880	157,401	—	—
Operating loss	(50,359)	(67,675)	(38,309)	(190,155)	(86,977)
Finance income/(expenses)	9,285	(53,657)	(22,686)	(15,766)	(12,138)
Net profit/loss for the year	(38,806)	(121,118)	(60,903)	(205,626)	(98,887)
Cash at bank and in hand	2	39	32,572	18,505	7,866
Total assets	78,145	25,296	102,214	55,415	43,224
Equity	(935,650)	(896,844)	(775,726)	(714,823)	(509,197)
Return on equity (%)*	(4.2)	(14.5)	(8.2)	(33.6)	(21.5)

Return on Equity: (Profit / (Loss) for the Year x 100) / Average Equity

Main activity

Ascendis Pharma Endocrinology Division A/S is a wholly owned subsidiary in the Ascendis Pharma Group, which is a global biopharmaceutical group focused on applying its innovative TransCon technology platform to make a meaningful difference for patients.

The Ascendis Pharma Group has developed a portfolio of product candidates by utilizing its TransCon technologies with clinically validated parent drugs. The primary focus of Ascendis Pharma Endocrinology Division A/S is activities directed towards the development of improved products within growth hormone deficiency.

Financial Review

The company's income statement for the year ended December 31, 2025 shows a net loss of €38.8 million, compared to a net loss €121.1 million for the year ended December 31, 2024, and the equity as of December 31, 2025, presented a deficit of €935.7 million compared to a deficit of €896.8 million for the year ended December 31, 2024. Further details about our results of operations are described below.

All employees in Denmark are employed by the Parent Company, Ascendis Pharma A/S, and accordingly, the Company has no employees. Furthermore, all expenses incurred by the Company, are being financed by the Parent Company. All intergroup transactions are made on an arms-length basis.

Development in the Company's Activities and Financial Position

The Company holds an equity position in VISEN Pharmaceuticals, which is presented as Capital interests on the balance sheet. Following the initial public offering ("IPO") in 2025, the Capital interest is measured at fair value through the income statement. In 2024 the Capital interest was measured at cost. Reference is made to note 9.

Revenue

Revenue for the year ended December 31, 2025 was €140.8 million, representing an increase of €17.9 million compared to last year. This increase was primarily attributable to higher revenue from collaboration partners.

Cost of Sales

Cost of sales for the year ended December 31, 2025, was €73.6 million, representing an increase of €33.6 million compared to last year. This increase was primarily attributable to higher revenue compared to 2024.

Research & Development Expenses

Research & development expenses for the year ended December 31, 2025 were €110.8 million representing a decrease of €0.1 million compared to last year. This decrease was primarily due to maturation of our product candidates.

Administrative Expenses

Administrative expenses for the year ended December 31, 2025, were €6.8 million representing a decrease of €32.9 million compared to last year. This decrease was primarily due to higher intergroup charges related to organizational growth in 2024.

Finance Income and Finance Expenses

Finance income and expenses (net) for the year ended December 31, 2025 were a net income of €9.3 million, representing an increase of €62.9 million compared to last year. This increase was primarily attributable to an increase in foreign exchange gain and remeasurement gain on financial assets and liabilities.

Going Concern

The Company has realized a loss for the year and lost its share capital. To support the Company, the Parent Company Ascendis Pharma A/S has confirmed the technical and financial support that it has committed and will further commit to the Company for the period until at least 30 June 2027.

Based on the circumstances described above, the financial statements are prepared by the Management on the basis that the Company is a going concern.

Research and Development Activities

Ascendis Pharma Endocrinology Division A/S is a wholly owned subsidiary in the Ascendis Pharma Group, which is a global biopharmaceutical group focused on applying its innovative TransCon technology platform to fulfill our mission of developing new therapies that demonstrate best-in-class potential to address unmet medical needs.

The Ascendis Pharma Group has created a portfolio of product candidates by applying its TransCon technologies to clinically validated parent drugs. The primary focus of Ascendis Pharma Endocrinology Division A/S is activities directed towards the development of improved products within growth hormone deficiency.

All external project-related expenses incurred by the Company, are being financed by the Parent Company. All directly related project expenses are invoiced to the Company who owns the license rights within the field of growth hormone deficiency.

Corporate Responsibility

Pursuant to section 99a (7) of the Danish Financial Statements Act. The company is referring to the Parent Company Ascendis Pharma A/S for corporate responsibility reporting.

Data Ethics

Pursuant to section 99d (3) of the Danish Financial Statements Act The company is referring to the Parent Company Ascendis Pharma A/S for a description on data ethic policies.

Events after the Balance Sheet Date

No events have occurred after the reporting date that would influence the evaluation of the financial statements.

Outlook

Having achieved pivotal milestones in 2025, the Ascendis Pharma Group expects continued global commercial growth, and development of operating expenses to support growth.

The Company is listed under the symbol “ASND” in the United States on The Nasdaq Global Select Market, where the Company at the time of approval of this annual report, has not provided a quantitative financial outlook. Accordingly, and due to equal information to investors, no further outlook is disclosed in this annual report.

Income Statement 1 January - 31 December

(EUR'000)	Note	2025	2024
Revenue	3	140,817	122,880
Cost of sales		(73,632)	(39,996)
Gross profit/(loss)		67,185	82,884
Research and development expenses		(110,788)	(110,886)
Administrative expenses		(6,756)	(39,673)
Operating profit/(loss)		(50,359)	(67,675)
Finance income	6	92,613	12,042
Finance expenses	6	(83,328)	(65,699)
Profit/(loss) before tax		(41,074)	(121,332)
Tax on profit/(loss) for the year	7	2,268	214
Net profit/(loss) for the year		(38,806)	(121,118)
Distribution of profit/(loss)			
Retained earnings		(38,806)	(121,118)

Balance Sheet 31 December

(EUR'000)	Note	2025	2024
Assets			
Property, plant and equipment	8	53	74
Fixed assets		53	74
Capital interests	9	73,760	22,504
Financial assets		73,760	22,504
Non-current assets		73,813	22,578
Trade receivables		865	533
Other receivables		2,054	688
Prepayments		1,411	1,458
Receivables		4,330	2,679
Cash at bank and in hand		2	39
Current assets		4,332	2,718
Total assets		78,145	25,296
Equity and liabilities			
Equity			
Share capital	11	134	134
Retained earnings		(935,784)	(896,978)
Total equity		(935,650)	(896,844)
Debt to credit institutions		110,684	142,008
Payables to group enterprises		874,480	759,354
Deferred income	12	—	5,000
Non-current liabilities		985,164	906,362
Debt to credit institutions		15,691	14,828
Payables to group enterprises		11,032	—
Deferred income	12	1,894	936
Accounts payables		14	14
Current liabilities		28,631	15,778
Total liabilities		1,013,795	922,140
Total equity and liabilities		78,145	25,296
Going concern	1		
Accounting policies	2		
Staff	4		
Fee to auditor	5		
Deferred tax	10		
Contingent liabilities and other financial obligations	13		
Related parties transactions	14		
Consolidated financial statements	15		
Subsequent events	16		

Statement of Changes in Equity

(EUR'000)

	<u>Share Capital</u>	<u>Retained Earnings</u>	<u>Total</u>
Equity at January 1, 2024	134	(775,860)	(775,726)
Net profit/(loss) for the year	—	(121,118)	(121,118)
Equity at December 31, 2024	134	(896,978)	(896,844)
Net profit/(loss) for the year	—	(38,806)	(38,806)
Equity at December 31, 2025	<u>134</u>	<u>(935,784)</u>	<u>(935,650)</u>

Notes to the Financial Statements

Note 1 - Going Concern

The Company has realized a net loss for the year and lost its share capital. To support the Company, the Parent Company Ascendis Pharma A/S has confirmed the technical and financial support that it has committed and will further commit to the Company for the period until at least 30 June 2027.

Ascendis Pharma A/S undertakes to make all reasonable technical efforts to support the Company to conduct all pre-clinical, manufacturing, clinical and regulatory activities with its product candidates for the period until at least 30 June 2027. Ascendis Pharma A/S undertakes to provide the Company with the necessary funds to ensure that the Company can conduct its activities for the period in compliance with The Danish Company Regulation and to ensure that the Company can meet its financial obligations as they fall due during the period until at least 30 June 2027.

Note 2 – Accounting Policies

Basis of Preparation

The Annual Report of Ascendis Pharma Endocrinology Division A/S for 2025 has been prepared in accordance with the provisions of the Danish Financial Statements Act according to enterprises of reporting class large C.

The accounting policies applied remain unchanged from last year.

Cash Flow Statement

Pursuant to section 86(4) of the Danish Financial Statements Act, the Company has not prepared a cash flow statement, as this is included in the cash flow statement for the Group in the financial statements of the Parent Company Ascendis Pharma A/S.

Foreign Currency

Translation Policies

Transactions in foreign currencies are measured at the exchange rate at the date of the transaction.

Receivables, payables and other monetary items in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date.

Exchange rate differences between the exchange rate at the date of the transaction and the exchange rate on either the payment date or the balance sheet date are recognized in the income statement as finance income or expenses.

Fixed assets and other non-monetary assets acquired in foreign currencies are measured at historical exchange rates.

Revenue

Revenue is recognized when it is probable that future economic benefits will flow to the Company and the benefits can be measured reliably. Recognition moreover requires that all material risks and rewards of the ownership of the rights and services related to arrangements have been transferred to the buyer.

Earnings from multiple-element arrangements, where the individual elements of the arrangements cannot be separated are recognized over the term of the arrangement. Where not all of these risks and rewards have been transferred, revenue is recognized as deferred income until all elements of the arrangement have been delivered.

Revenue is recognized exclusive of VAT, indirect taxes and net of discounts relating to sales and is measured at the fair value of the determined consideration.

The Company owns license rights within the field of growth hormone deficiency, where the products are manufactured and owned by the Parent Company Ascendis Pharma A/S. Since the Company, contractually, acts as a principal over commercial sales, revenue and cost of sales are presented on a gross basis. Commercial sales are facilitated by other group entities. All intergroup transactions are made on an arm's-length basis.

Research and Development Expenses

Research and development expenses comprise expenses incurred to develop the Company's products and to deliver the services under the Company's collaboration agreements. Research and development expenses are recognized in the income statement as incurred.

Administrative Expenses

Administrative expenses comprise expenses for management, administration services, sales related expenses, office supplies, cost of facilities, professional fees, and depreciation of non-current assets related to administrative activities.

Finance Income and Expenses

Finance income and expenses comprise interest income and expenses and realized and unrealized exchange rate gains and losses on transactions denominated in foreign currencies, fair value remeasurement gains and losses on capital interests and remeasurement gains and losses on debt to credit institutions.

Interest income and interest expenses are stated on an accrual basis using the principal and the effective interest rate. The effective interest rate is the discount rate that is used to discount expected future cash payments or receipts through the expected life of the financial asset or financial liability to the amortized cost (the carrying amount), of such asset or liability.

Tax on Profit/(Loss) for the Year

Tax for the year, which consists of current tax for the year and changes in prior years tax is recognized in the income statement. The current tax payable or receivable is recognized in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax.

When computing the current tax for the year, the tax rates and tax rules enacted or substantially enacted at the reporting date are used. Current tax payable is based on taxable profit or loss for the year. Taxable profit or loss differs from net profit or loss, as reported in the income statement because it excludes items of income or expenses that are taxable or deductible in prior or future years. In addition, taxable profit or loss excludes items that are never taxable or deductible.

Property, Plant and Equipment

Property, plant and equipment are measured at cost less accumulated depreciation and less any accumulated impairment losses. Cost comprises the cost of acquisition and expenses directly related to the acquisition up until the time when the asset is ready for use.

Depreciation is calculated on a straight-line basis, based on an asset's expected useful life, being within 5- 10 years for plant and machinery.

Depreciation methods, useful lives and residual amounts are reassessed at least annually.

Capital Interests

Until 2024, capital interests were measured at cost. As a consequence of the IPO of the Company's capital interests in 2025, capital interests are from 2025 subsequently measured at fair value through the income statement.

Receivables

Receivables comprise trade receivables, receivables from group enterprises, income tax receivables and other receivables.

Trade receivables are classified as financial assets at amortized cost, as these are held to collect contractual cash flows and thus give rise to cash flows representing solely payments of principal and interest. Trade receivables are initially recognized at their transaction price and subsequently measured at amortized cost. Income tax receivables and other receivables related to deposits, VAT and other indirect taxes are measured at cost less impairment. Carrying amounts of receivables usually equals their nominal value less, provision for impairments.

Prepayments

Prepayments comprise advance payments relating to a future financial period. Prepayments are measured at cost.

Cash at Bank and in Hand

Cash at bank and in hand comprise cash and cash equivalents and are measured at amortized cost.

Shareholders' Equity

The share capital comprises the nominal amount of ordinary shares, each at a nominal value of DKK 1, or approximately €0.13. All shares are fully paid.

Retained earnings/(accumulated deficit) represents the accumulated profits or losses from the Company's operations. A positive reserve is available to be distributed as dividends to the Company's shareholders.

Debt to Credit Institutions

Debt to credit institutions is recognized initially at fair value net of incremental transaction costs. Subsequently, debt to credit institutions is measured at amortized cost. The effective interest rate is estimated at initial recognition and takes into account incremental transaction costs and anticipated amount and timing of future cash flows.

The amortized cost is remeasured prospectively when there is a material change in expectations to amount and timing of future cash flows, which will increase or decrease future interest expenses. Remeasurement gain or losses are recognized through the income statement as finance income or expenses, respectively.

Accounts Payables

Accounts payable are measured at amortized cost.

Deferred Income

Deferred income comprises deferred income from collaboration agreements and license agreements, where consideration received does not match the individual deliverables with respect to amount and satisfied performance obligations.

Deferred income is measured at the fair value of the consideration received and is recognized as revenue in the statement of profit or loss when the relevant performance obligation, to which the deferred income relates, is satisfied.

Note 3 – Revenue

Revenue is primarily related to sales of commercial products, which for 2025 and 2024 were mainly in North America.

Note 4 – Staff

	2025	2024
Average number of employees	<u>0</u>	<u>0</u>

The Company has no employees. The Executive Board consist of one person, who receives remuneration from another Ascendis Group company. The Company is charged a management fee by the Parent Company.

Note 5 – Fee to Auditor

Pursuant to section 96 (3) of the Danish Financial Statements Act, principal accountant fee and services are disclosed in the financial statements of the Parent Company.

Note 6 – Finance Income and Expenses

(EUR'000)	2025	2024
Finance income		
Interest income	13	230
Interest income from group enterprises	—	1,289
Remeasurement gain on financial assets and liabilities	71,724	10,523
Exchange rate gains (net)	20,876	—
Total finance income	<u>92,613</u>	<u>12,042</u>
Finance expenses		
Interest expenses	19,900	19,674
Interest expenses to group enterprises	63,428	29,347
Exchange rate losses (net)	—	16,678
Total finance expenses	<u>83,328</u>	<u>65,699</u>

Note 7 – Tax on Profit/(Loss) for the Year

(EUR'000)	2025	2024
Tax on profit/(loss) for the year:		
Current tax (expense)/income	2,317	275
Current tax (expense)/income, adjustments to prior years	(49)	(61)
Total tax on profit/(loss) for the year	<u>2,268</u>	<u>214</u>

Note 8 – Property, Plant and Equipment

(EUR'000)	Plant and machinery
Cost	
January 1, 2024	520
December 31, 2024	520
December 31, 2025	520
Depreciation and impairment	
January 1, 2024	(423)
Depreciation charge	(23)
December 31, 2024	(446)
Depreciation charge	(21)
December 31, 2025	(467)
Carrying amount	
December 31, 2024	74
December 31, 2025	53

Note 9 – Capital Interests

The Company holds an equity position in VISEN Pharmaceuticals, which is presented as capital interests in the balance sheet. VISEN Pharmaceuticals closed an IPO on March 21, 2025 (Stock Code: 2561.HK).

Up until the IPO, the equity position was measured at cost. Following the IPO, the equity position is measured at fair value through the income statement. Fair value can be measured based on quoted prices in active markets (fair value level 1).

The cost as of December 31, 2024 was €22,504 thousand. The unrealized gain/(loss) recognized in the income statement during the year was €51,256 thousand. The fair value as of December 31, 2025 was €73,760 thousand.

Following information relates to the capital interest in VISEN Pharmaceuticals.

Capital interest	Domicile	Ownership	RMB'000 Equity*	RMB'000 Profit/(loss) for the period*
VISEN Pharmaceuticals	Cayman Island	19.6%	241,275	(182,242)

*Annual report 2024

Note 10 – Deferred Tax

(EUR'000)	2025	2024
Specification of deferred tax assets/(liabilities)		
Tax deductible losses	178,291	175,750
Other temporary differences, assets	36,889	31,805
Deferred tax asset, not recognized	(215,180)	(207,555)
Total deferred tax assets/(liabilities) at December, 31	—	—

Deferred tax assets have not been recognized in the statements of financial position as of December 31, 2025 due to uncertainty relating to future utilization. The deferred tax asset can be carried forward without timing limitations. Any deferred tax liabilities can be offset in deferred tax assets within the Danish joint taxation group.

Note 11 – Share Capital

The share capital of Ascendis Pharma Endocrinology Division A/S consists of 1.000.000 fully paid ordinary shares at a nominal value of DKK 1, all in the same share class.

Note 12 – Deferred Income

The Company entered into long-term contracts with customers, comprising unsatisfied performance obligations related to delivery of commercial supplies under the Company's license agreements. Current contract liabilities are expected to be recognized as revenue within 1 year.

Note 13 – Contingent Liabilities and Other Financial Obligations

The Danish group companies of Ascendis Pharma A/S are jointly and severally liable for tax on the Danish group's jointly taxed income.

The Danish group companies of Ascendis Pharma A/S are jointly registered for Danish VAT, and the Danish group is jointly liable for the payment thereof.

Note 14 – Related Party Transactions

The Executive board and the Board of Directors are considered related parties as they have authority and responsibility for planning and directing the Company's operations. Additionally, all group enterprises, and associates of group enterprises, are considered related parties.

The Company is wholly owned by the Parent Company Ascendis Pharma A/S.

Transactions between the Company and group enterprises comprise research and development services, clinical supplies, commercial supplies and sales and administrative services.

In addition, the Company is jointly taxed with Ascendis Pharma A/S and its Danish subsidiaries, where the current Danish corporation tax is allocated between the jointly taxed Danish companies.

Except for the information disclosed above, the Company has not undertaken any significant transactions with members of management, or undertakings in which the identified related parties have a controlling or joint controlling interest.

Pursuant to section 98c(7) of the Danish Financial Statements Act, transactions with related parties have not been disclosed in the financial statements, as they have been made on an arm's length basis.

Note 15 - Consolidated Financial Statements

The Company is wholly owned by and included in the Group Annual Report of the Parent Company Ascendis Pharma A/S.

Name	Place of Registered Office
Ascendis Pharma A/S	Copenhagen, Denmark

Note 16 – Subsequent Events

No events have occurred after the reporting date that would influence the evaluation of the financial statements.